Ultragenyx Pharmaceutical Inc
Most Recent
PTC Therapeutics to Acquire Agilis Biotherapeutics
On July 19, PTC Therapeutics (PTCT) agreed to acquire Agilis Biotherapeutics. The acquisition is expected to close during Q3 2018.
Company & Industry Overviews Discretionary Stocks Boost the Wells Fargo Growth Fund in YTD 2016
Early 2016 was not generous to the Wells Fargo Growth Fund – Class A (SGRAX), and the fund was a below-average performer until May. However, things have improved since then.
Can XBI Continue the Upward Trend It Achieved in May?
The SPDR S&P Biotech ETF (XBI) reflected the performance of SPY and rose 0.2%, continuing its upward trend. XBI had a good month in May and began June on a positive note.
Company & Industry Overviews How the Consumer Discretionary Sector Has Affected SGRAX in 2016
The Wells Fargo Growth Fund Class A (SGRAX) had fallen by 1% year-to-date (or YTD) in 2016 as of May 27, 2016.
IBB’s Mid-Cap Stocks: Kite Pharma Drug Gets Orphan Drug Status
IBB’s mid-cap holding Kite Pharma (KITE) rose by 3.3% on the news of the FDA granting orphan drug status to Kite’s KTE-C19.
Mid-Cap Stock Update: Horizon Tanks 21% on Earnings Concerns
In the mid-cap space, Horizon Pharma (HZNP) was the worst hit, falling by 21% for the week ended April 15, 2016.
XBI News as of March 16: Mid-Caps Under Pressure
Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.
Ultragenyx Woos Investors with Good Returns in Mid-Cap Space
Ultragenyx Pharmaceutical (RARE) rebounded on December 14, 2015, after falling for four consecutive days. The stock rose 3.8% and was the top performer among the mid-cap stocks that day.
Moving Averages of XBI’s Holdings Have Improved
The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.
Shire-Dyax Merger Drove Biotech Stocks
Shire (SHPG) announced that it will acquire Dyax (DYAX) for $37.30 per Dyax share in a deal valued at ~$5.9 billion.
Ultragenyx: A Top Loser in the Biotechnology Subgroup
Ultragenyx Pharmaceutical (RARE) fell by 8.2% due to profit-booking. It had a high trading volume of ~700,000 shares. The stock closed at $86.99.
